Wang Yuxiao, Li Jingxin, Hu Yuemei, Liang Qi, Wei Mingwei, Zhu Fengcai
a School of Public Health; Southeast University , Nanjing , PR China.
b Jiangsu Provincial Center for Disease Control and Prevention , Nanjing , PR China.
Hum Vaccin Immunother. 2017 Jan 2;13(1):153-168. doi: 10.1080/21645515.2016.1225637. Epub 2016 Oct 20.
Ebola virus disease (EVD) has become a great threat to humans across the world in recent years. The 2014 Ebola epidemic in West Africa caused numerous deaths and attracted worldwide attentions. Since no specific drugs and treatments against EVD was available, vaccination was considered as the most promising and effective method of controlling this epidemic. So far, 7 vaccine candidates had been developed and evaluated through clinical trials. Among them, the recombinant vesicular stomatitis virus-based vaccine (rVSV-EBOV) is the most promising candidate, which demonstrated a significant protection against EVD in phase III clinical trial. However, several concerns were still associated with the Ebola vaccine candidates, including the safety profile in some particular populations, the immunization schedule for emergency vaccination, and the persistence of the protection. We retrospectively reviewed the current development of Ebola vaccines and discussed issues and challenges remaining to be investigated in the future.
近年来，埃博拉病毒病（EVD）已成为全球人类面临的巨大威胁。2014年西非埃博拉疫情导致众多人死亡，引起了全球关注。由于当时尚无针对埃博拉病毒病的特效药物和治疗方法，疫苗接种被认为是控制这一疫情最有前景且有效的方法。截至目前，已有7种候选疫苗通过临床试验进行了研发和评估。其中，基于重组水疱性口炎病毒的疫苗（rVSV-EBOV）是最具前景的候选疫苗，在III期临床试验中显示出对埃博拉病毒病的显著保护作用。然而，埃博拉候选疫苗仍存在一些问题，包括某些特定人群的安全性、紧急接种的免疫程序以及保护作用的持久性。我们回顾了埃博拉疫苗的当前研发情况，并讨论了未来仍有待研究的问题和挑战。
